BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

December 10, 2013

WALTHAM, Mass., Dec. 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT® Code 82777) at the amount of a crosswalked test (analyte-specific CPT® Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.

Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting

Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting

December 9, 2013

Preclinical In Vivo Efficacy Demonstrated for IDH Inhibitors in Patient-Derived Leukemia Models

CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that data from its lead programs were highlighted at the American Society of Hematology (ASH) Annual Meeting this week in New Orleans.

Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at 2013 American Society of Hematology Annual Meeting

Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at 2013 American Society of Hematology Annual Meeting

December 9, 2013

Dose-dependent increases in hemoglobin demonstrated in non-transfusion dependent patients Increases in hemoglobin of at least 1-2 g/dL observed in most patients at 0.3 and 0.5 mg/kg dose levels Significant relationship between hemoglobin increase and drug exposure across dose ranges tested

Sotatercept granted orphan status by the FDA for the treatment of beta-thalassemia

Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

December 5, 2013

— Data from Interim Analysis of Phase 2 Trial Provide Support to Advance Program —

— Interim Data Consistent with RPC1063 Differentiation Profile —

Software Industry Veteran Lou Shipley Named CEO of Black Duck Software

Software Industry Veteran Lou Shipley Named CEO of Black Duck Software

December 4, 2013

Extensive Experience in Cloud, Enterprise Software, Virtualization and CEO Roles Positions Black Duck for Accelerated Growth

Acceleron Pharma Provides Update on Clinical Pipeline at Piper Jaffray Healthcare Conference

Acceleron Pharma Provides Update on Clinical Pipeline at Piper Jaffray Healthcare Conference

December 3, 2013

Plans to initiate phase 2 study of dalantercept plus sorafenib in hepatocellular cancer in the first half of 2014

Remains on track to initiate pivotal trial with sotatercept or ACE-536 in late 2014 or early 2015

BIND Therapeutics Co-Founders Demonstrate Ability to Cross Biological Barriers with Targeted Therapeutic Nanoparticles

BIND Therapeutics Co-Founders Demonstrate Ability to Cross Biological Barriers with Targeted Therapeutic Nanoparticles

November 27, 2013

Data Published in Science Translational Medicine Offer Potential New Applications for BIND's Medicinal Nanoengineering Platform

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT

December 2, 2013

– Expands Company’s Therapeutic Pipeline for Infectious Diseases –

Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth

Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth

December 2, 2013

– Appoints David Arkowitz as Chief Operating Officer and Chief Financial Officer, and Greg Miller as Vice President of Business Development and Strategic Planning –

Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics

Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics

November 25, 2013

Company Founded by Five World Leaders in Genome Editing; Secures $43 Million Series A Financing Led by Flagship Ventures, Polaris Partners and Third Rock Ventures